Neutrophil‐to‐lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
Saved in:
| Title: | Neutrophil‐to‐lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis. |
|---|---|
| Authors: | Suzuki, Takanori1 (AUTHOR), Matsuura, Kentaro1 (AUTHOR) matsuura@med.nagoya-cu.ac.jp, Sobue, Satoshi2 (AUTHOR), Kato, Daisuke3 (AUTHOR), Hayashi, Katsumi3 (AUTHOR), Kondo, Hiromu4 (AUTHOR), Anbe, Kaiki5 (AUTHOR), Mizoshita, Tsutomu5 (AUTHOR), Okayama, Kohei6 (AUTHOR), Okumura, Fumihiro6 (AUTHOR), Kimura, Yoshihide7 (AUTHOR), Ozasa, Atsushi8 (AUTHOR), Inada, Hiroki9 (AUTHOR), Tokunaga, Takayuki9 (AUTHOR), Narahara, Satoshi9 (AUTHOR), Kawamura, Hayato1 (AUTHOR), Fujiwara, Kei1 (AUTHOR), Nojiri, Shunsuke1 (AUTHOR), Kataoka, Hiromi1 (AUTHOR), Tanaka, Yasuhito9 (AUTHOR) |
| Source: | Hepatology Research. Jun2025, Vol. 55 Issue 6, p883-895. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 13866346 |
|---|---|
| DOI: | 10.1111/hepr.14189 |
